Stingy funding cycle for startup biotechs

11/21/2013 | Xconomy

Despite solid returns on prior investments in biomedical firms, investors seem disinclined to finance new startups this year, Luke Timmerman writes. The number of first-time financings for life sciences companies through the first three quarters of 2013 was the lowest since 1996, according to data from Thomson Reuters. The number of active venture capital firms has declined over the last five years, and many big institutional investors do not believe that the rewards in life sciences investing justify the risks.

View Full Article in:

Xconomy

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT